| Primary | Number of Participants With One or More Adverse Events (AEs) | | | Posted | | Count of Participants | | Participants | | AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Number of Participants With Premature Treatment Discontinuation Due to AEs | | Subjects in the arm receiving only AB-720 and SOC NrtL were not evaluated for VBR discontinuation. Subjects in the arm reviewing only VBR and SOC NrtI were not evaluated for AB-720 discontinuation. | Posted | | Count of Participants | | Participants | | AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | |
|
| Primary | Number of Participants With One or More Abnormal Laboratory Result | | | Posted | | Count of Participants | | Participants | | Laboratory results were collected from the time of signing the informed consent until the study was early terminated, up to 96 weeks. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment | Subjects remained on their assigned oral agents (ie, VBR+NrtI for Groups 1 and 2; NrtI for Group 3) until Week 48 laboratory results required for Treatment Stopping Criteria assessment were available so there are some results past Week 48. | The number analyzed differs from the overall number analyzed due to early terminated and/or withdrawn subjects. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC Nrtl | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Number of Participants With Serum HBsAg Below the Lower Limit of Quantitation (<LLOQ) | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Pre-specified time points up to 96 weeks | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Number of Participants With HBV Deoxyribonucleic Acid (DNA) Not Detected (<5 IU/mL) | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Number of Participants With HBV Ribonucleic Acid (RNA) <LLOQ | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Change From Baseline in Mean log10 HBV RNA On-Treatment | Subjects remained on their assigned oral agents (ie, VBR+NrtI for Groups 1 and 2; NrtI for Group 3) until Week 48 laboratory results required for Treatment Stopping Criteria assessment were available so there are some results past Week 48. | The number analyzed differs from the overall number analyzed due to early terminated and/or withdrawn subjects. | Posted | | Mean | Standard Deviation | log10 U/mL | | Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) On-Treatment | | The number analyzed differs from the overall number analyzed due to early terminated and/or withdrawn subjects. | Posted | | Mean | Standard Deviation | log10 U/mL | | Baseline and Week 48 | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | |
|
| Secondary | Number of Participants With HBsAg Seroconversion | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Number of Participants With Normal Alanine Aminotransferase (ALT) | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Baseline and at pre-specified time points up to 96 weeks | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Plasma Levels of VBR | | Due to early termination of the study, data were not collected and analyzed for secondary outcomes. | Posted | | | | | | Before dosing at Baseline (Day 1) and at pre-specified time points up to 48 weeks, and at Week 52 | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Plasma Levels of AB-729 | | Due to early termination of the study, data were not collected and analyzed for secondary outcomes. | Posted | | | | | | 2 hours after dosing at pre-specified time points up to 40 weeks | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Plasma Levels of SOC NrtI (ETV, TDF, TAF) | | Due to early termination of the study, data was not collected or analyzed for secondary outcomes. | Posted | | | | | | Before dosing at Baseline (Day 1) and at pre-specified time points up to 48 weeks | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + SOC NrtI | Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. This treatment was used as a reference regimen. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 | AB-729 + SOC NrtI | Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until the study was early terminated. This treatment was used as a reference regimen. AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. |
|
| Secondary | Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment | | Not all subjects reached Week 96 due to study termination. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI (Discontinued All) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + AB-720 + SOC NrtI (Continued NrtI Only) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | |
|
| Secondary | Change From Baseline in Mean log10 HBV RNA Off-Treatment | | Due to study early termination, not all subjects reached week 96. | Posted | | Mean | Standard Deviation | log10 U/mL | | Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI (Discontinued All) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + AB-720 + SOC NrtI (Continued NrtI Only) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG002 |
|
| Secondary | Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) Off-Treatment | | Due to study early termination, not all subjects reached week 96. | Posted | | Mean | Standard Deviation | log10 U/mL | | Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96. | | | | ID | Title | Description |
|---|
| OG000 | VBR + AB-729 + SOC NrtI (Discontinued All) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | | OG001 | VBR + AB-720 + SOC NrtI (Continued NrtI Only) | Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up or until study was early terminated. VBR: VBR is an HBV core protein inhibitor. Participants received VBR 300 mg tablets orally once daily (QD). AB-729: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants received a 60-mg subcutaneous injection of AB-729 once every 8 weeks. SOC NrtI: Participants received their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert. | |
|